File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration

TitleAqueous and vitreous penetration of linezolid (Zyvox) after oral administration
Authors
Issue Date2004
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophtha
Citation
Ophthalmology, 2004, v. 111 n. 6, p. 1191-1195 How to Cite?
AbstractObjective To investigate the penetration of linezolid, a synthetic oxazolidinone antibiotic, into the aqueous and vitreous humor after oral administration. Design Noncomparative interventional, prospective case series study, randomized into group 1 (dose, one 600-mg tablet) or group 2 (2 doses of 600 mg given 12 hours apart). Participants Patients undergoing pars plana vitrectomy between March 2001 and August 2002 at the University of Illinois at Chicago Eye Center who had not had prior vitrectomy surgery. Methods Aqueous, vitreous, and plasma samples were obtained and analyzed from 29 patients after oral administration of 1 dose (group 1A, 13 patients [13 eyes] sampled less than 2 hours after administration; group 1B, 9 patients [9 eyes] sampled more than 2 hours after administration) or 2 doses 12 hours apart (group 2, 7 patients [7 eyes]) before surgery. Main outcome measures Aqueous, vitreous, and plasma concentrations of linezolid (micrograms per milliliter). Results Group 1A achieved mean aqueous, vitreous, and plasma levels of 0.77±0.6 μg/mL, 0.3±0.3 μg/mL, and 5.0±3.3 μg/mL, respectively. Group 1B achieved mean aqueous, vitreous, and plasma levels of 3.8±1.2 μg/mL, 2.3±1.4 μg/mL, and 7.6±2.7 μg/mL, respectively. Group 2 achieved mean aqueous, vitreous, and plasma levels of 6.6±2.7 μg/mL, 5.7±2.7 μg/mL, and 10.3±4.1 μg/mL, respectively. Conclusions Mean inhibitory aqueous and vitreous minimum inhibitory concentrations for 90% of isolates (MIC 90) were achieved against all gram-positive bacteria, including vancomycin-resistant enterococcus, methicillin-resistant Staphylococcus aureus, and streptococcal species after 2 doses given 12 hours apart. Mean MIC 90 were achieved for many gram-positive pathogens after only one dose in many patients after approximately 4 hours. © 2004 by the American Academy of Ophthalmology.
Persistent Identifierhttp://hdl.handle.net/10722/176434
ISSN
2015 Impact Factor: 6.75
2015 SCImago Journal Rankings: 4.745
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFiscella, RGen_US
dc.contributor.authorLai, WWen_US
dc.contributor.authorBuerk, Ben_US
dc.contributor.authorKhan, Men_US
dc.contributor.authorRodvold, KAen_US
dc.contributor.authorPulido, JSen_US
dc.contributor.authorLabib, Sen_US
dc.contributor.authorShapiro, MJen_US
dc.contributor.authorBlair, NPen_US
dc.date.accessioned2012-11-26T09:11:15Z-
dc.date.available2012-11-26T09:11:15Z-
dc.date.issued2004en_US
dc.identifier.citationOphthalmology, 2004, v. 111 n. 6, p. 1191-1195en_US
dc.identifier.issn0161-6420en_US
dc.identifier.urihttp://hdl.handle.net/10722/176434-
dc.description.abstractObjective To investigate the penetration of linezolid, a synthetic oxazolidinone antibiotic, into the aqueous and vitreous humor after oral administration. Design Noncomparative interventional, prospective case series study, randomized into group 1 (dose, one 600-mg tablet) or group 2 (2 doses of 600 mg given 12 hours apart). Participants Patients undergoing pars plana vitrectomy between March 2001 and August 2002 at the University of Illinois at Chicago Eye Center who had not had prior vitrectomy surgery. Methods Aqueous, vitreous, and plasma samples were obtained and analyzed from 29 patients after oral administration of 1 dose (group 1A, 13 patients [13 eyes] sampled less than 2 hours after administration; group 1B, 9 patients [9 eyes] sampled more than 2 hours after administration) or 2 doses 12 hours apart (group 2, 7 patients [7 eyes]) before surgery. Main outcome measures Aqueous, vitreous, and plasma concentrations of linezolid (micrograms per milliliter). Results Group 1A achieved mean aqueous, vitreous, and plasma levels of 0.77±0.6 μg/mL, 0.3±0.3 μg/mL, and 5.0±3.3 μg/mL, respectively. Group 1B achieved mean aqueous, vitreous, and plasma levels of 3.8±1.2 μg/mL, 2.3±1.4 μg/mL, and 7.6±2.7 μg/mL, respectively. Group 2 achieved mean aqueous, vitreous, and plasma levels of 6.6±2.7 μg/mL, 5.7±2.7 μg/mL, and 10.3±4.1 μg/mL, respectively. Conclusions Mean inhibitory aqueous and vitreous minimum inhibitory concentrations for 90% of isolates (MIC 90) were achieved against all gram-positive bacteria, including vancomycin-resistant enterococcus, methicillin-resistant Staphylococcus aureus, and streptococcal species after 2 doses given 12 hours apart. Mean MIC 90 were achieved for many gram-positive pathogens after only one dose in many patients after approximately 4 hours. © 2004 by the American Academy of Ophthalmology.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ophthaen_US
dc.relation.ispartofOphthalmologyen_US
dc.subject.meshAcetamides - Administration & Dosage - Pharmacokineticsen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAnti-Infective Agents - Administration & Dosage - Pharmacokineticsen_US
dc.subject.meshAqueous Humor - Metabolismen_US
dc.subject.meshBiological Availabilityen_US
dc.subject.meshChromatography, High Pressure Liquiden_US
dc.subject.meshFemaleen_US
dc.subject.meshGas Chromatography-Mass Spectrometryen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOxazolidinones - Administration & Dosage - Pharmacokineticsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshProtein Synthesis Inhibitors - Administration & Dosage - Pharmacokineticsen_US
dc.subject.meshVitrectomyen_US
dc.subject.meshVitreous Body - Metabolismen_US
dc.titleAqueous and vitreous penetration of linezolid (Zyvox) after oral administrationen_US
dc.typeArticleen_US
dc.identifier.emailLai, WW: wicolai@hku.hken_US
dc.identifier.authorityLai, WW=rp00531en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ophtha.2003.09.042en_US
dc.identifier.pmid15177970-
dc.identifier.scopuseid_2-s2.0-2942582420en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-2942582420&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume111en_US
dc.identifier.issue6en_US
dc.identifier.spage1191en_US
dc.identifier.epage1195en_US
dc.identifier.isiWOS:000221708100017-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridFiscella, RG=15026310600en_US
dc.identifier.scopusauthoridLai, WW=7402231098en_US
dc.identifier.scopusauthoridBuerk, B=6506554414en_US
dc.identifier.scopusauthoridKhan, M=35082278200en_US
dc.identifier.scopusauthoridRodvold, KA=7005893571en_US
dc.identifier.scopusauthoridPulido, JS=20135697200en_US
dc.identifier.scopusauthoridLabib, S=7003915594en_US
dc.identifier.scopusauthoridShapiro, MJ=35447792900en_US
dc.identifier.scopusauthoridBlair, NP=7005095959en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats